Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 7, 2015, Pages 330.e19-330.e25

  Muralidhar, Vinayak ^a   Dinh, Kathryn T ^b   Mahal, Brandon A ^b   Ziehr, David R ^b   Chen, Yu Wei ^c   Viswanathan, Vidya B ^d   Nezolosky, Michelle D ^d   Choueiri, Toni K ^d   Hoffman, Karen E ^e   Hu, Jim C ^d   Sweeney, Christopher J ^d   Trinh, Quoc Dien ^d   Nguyen, Paul L ^d  

^a HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Androgen deprivation therapy; Occult T3; Prostate cancer; Prostate MRI; Upstaging

Indexed keywords

ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; ANDROGEN RECEPTOR ANTAGONIST;

ADULT; ANDROGEN DEPRIVATION THERAPY; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER REGISTRY; CANCER RISK; CANCER SIZE; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CANCER SURGERY; CAUCASIAN; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; ADENOCARCINOMA; FACTUAL DATABASE; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS;

ADENOCARCINOMA; ANDROGEN RECEPTOR ANTAGONISTS; DATABASES, FACTUAL; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84930571420     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2015.03.010     Document Type: Article

References (37)

1. U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999-2011 Incidence and mortality web-based report. Atlanta (GA): Department of Health and Human Services, Centers for Disease Control and Prevention, and National Cancer Institute; 2014.
2. Prostate Cancer; 2014. http://www.cancer.gov/cancertopics/types/prostate.
3. Bolla M., De Reijke T.M., van Tienhoven G., Van den Bergh A.C., Oddens J., Poortmans P.M., et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360:2516-2527.
4. Hegde J.V., Chen M.H., Mulkern R.V., Fennessy F.M., D'Amico A.V., Tempany C.M. Preoperative 3-Tesla multiparametric endorectal magnetic resonance imaging findings and the odds of upgrading and upstaging at radical prostatectomy in men with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2013, 85:e101-e107.
5. Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database: Incidence-SEER 9 Regs Research Data, 2013 Sub (1973-2011)- Linked To County Attributes - Total U.S., 1969-2012 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2014, based on the November 2013 submission. http://www.seer.cancer.gov.
6. AJCC Cancer Staging Manual 2010, Springer, New York, NY. 7th ed. S. Edge, D.R. Byrd, C.C. Compton, F.L. Green, A. Trotti (Eds.).
7. Fine J., Gray R. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
8. Curtin F., Schulz P. Multiple correlations and Bonferroni's correction. Biol Psychiatry 1998, 44:775-777.
9. D'Amico A.V., Schnall M., Whittington R., et al. Endorectal coil magnetic resonance imaging identifies locally advanced prostate cancer in select patients with clinically localized disease. Urology 1998, 51:449-454.
10. Feng T.S., Sharif-afshar A.R., Smith S.C., et al. Multiparametric magnetic resonance imaging localizes established extracapsular extension of prostate cancer. Urol Oncol 2014.
11. Roethke M.C., Lichy M.P., Kniess M., Werner M.K., Claussen C.D., Stenzl A., et al. Accuracy of preoperative endorectal MRI in predicting extracapsular extension and influence on neurovascular bundle sparing in radical prostatectomy. World J Urol 2013, 31:1111-1116.
12. Cerantola Y., Valerio M., Kawkabani Marchini A., Meuwly J.Y., Jichlinski P. Can 3 T multiparametric magnetic resonance imaging accurately detect prostate cancer extracapsular extension?. Can Urol Assoc J 2013, 7:E699-E703.
13. Somford D.M., Hamoen E.H., Futterer J.J., van Basten J.P., Hulsbergenvan de Kaa C.A., Vreuls W., et al. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol 2013, 190:1728-1734.
14. Ikonen S., Kärkkäinen P., Kivisaari L., et al. Magnetic resonance imaging of clinically localized prostatic cancer. J Urol 1998, 159:915-919.
15. Soylu F.N., Peng Y., Jiang Y., et al. Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging. Radiology 2013, 267:797-806.
16. Sala E., Akin O., Moskowitz C.S., et al. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. Radiology 2006, 238:929-937.
17. Perrotti M., Kaufman R.P., Jennings T.A., et al. Endo-rectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate?. J Urol 1996, 156:106-109.
18. Makarov D.V., Desai R.A., Yu J.B., et al. The population level prevalence and correlates of appropriate and inappropriate imaging to stage incident prostate cancer in the Medicare population. J Urol 2012, 187:97-102.
19. Cooperberg M.R., Lubeck D.P., Grossfeld G.D., Mehta S.S., Carroll P.R. Contemporary trends in imaging test utilization for prostate cancer staging: data from the cancer of the prostate strategic urologic research endeavor. J Urol 2002, 168:491-495.
20. D'Amico A.V., Manola J., Loffredo M., et al. 6-month androgen suppression plus radiation therapy vs. radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. J Am Med Assoc 2004, 292:821-827.
21. Tempany C.M., Zhou X., Zerhouni E.A., Rifkin M.D., Quint L.E., Piccoli L.W., et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994, 192:47-54.
22. Roach M. Current trends for the use of androgen deprivation therapy in conjunction with radiotherapy for patients with unfavorable intermediate-risk, high-risk, localized, and locally advanced prostate cancer. Cancer 2014, 120:1620-1629.
23. Greene D.E., Mayadev J.S., Valicenti R.K. Radiation treatment for patients with intermediate-risk prostate cancer. Ther Adv Urol 2012, 4:113-124.
24. Tempany C.M., Zhou X., Zerhouni E.A., et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994, 192:47-54.
25. Langlotz C., Schnall M., Pollack H. Staging of prostatic cancer: accuracy of MR imaging. Radiology 1995, 194:645-646.
26. Harris R.D., Schned A.R., Heaney J.A. Staging of prostate cancer with endorectal MR imaging: lessons from a learning curve. RadioGraphics 1995, 15:813-829.
27. Mullerad M., Hricak H., Wang L., et al. Prostate cancer: detection of extracapsular extension by genitourinary and general body radiologists at MR imaging. Radiology 2004, 232:140-146.
28. Porter C.R., Kodama K., Gibbons R.P., et al. 25-year prostate cancer control and survival outcomes: a 40-year radical prostatectomy single institution series. J Urol 2006, 176:569-574.
29. Roehl K.A., Han M., Ramos C.G., Antenor J.A., Catalona W.J. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3478 consecutive patients: long-term results. J Urol 2004, 172:910-914.
30. Chun F.K., Graefen M., Zacharias M., et al. Anatomic radical retropubic prostatectomy-long-term recurrence-free survival rates for localized prostate cancer. World J Urol 2006, 24:273-280.
31. Iselin C.E., Robertson J.E., Paulson D.F. Radical perineal prostatectomy: oncological outcome during a 20-year period. J Urol 1999, 161:63-68.
32. Paulson D.F., Moul J.W., Walther P.J. Radical prostatectomy for clinical stage T1-2N0M0 prostatic adenocarcinoma: long-term results. J Urol 1990, 144:1180-1184.
33. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. J Am Med Assoc 1998, 280:969-974.
34. Giordano S.H., Kuo Y.F., Duan Z., Hortobagyi G.N., Freeman J., Goodwin J.S. Limits of observational data in determining outcomes from cancer therapy. Cancer 2008, 112:2456-2466.
35. Mygatt J., Sesterhenn I., Rosner I., et al. Anterior tumors of the prostate: clinicopathological features and outcomes. Prostate Cancer Prostatic Dis 2014, 17:75-80.
36. Nguyen M.M., Gill I.S. Coded tumor size may be unreliable for small metastatic renal cancers in the surveillance, epidemiology, and end results dataset. Urology 2010, 75:266.
37. Shah S.K., Fleet T.M., Williams V., et al. SEER coding standards result in underestimation of positive surgical margin incidence at radical prostatectomy: results of a systematic audit. J Urol 2011, 186:855-859.